Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decitabine.

Jean-Pierre Issa1

  • 1Department of Leukemia, M. D. Anderson Cancer Center, Houston, TX 77030, USA. jpissa@mdanderson.org

Current Opinion in Oncology
|November 19, 2003
PubMed
Summary
This summary is machine-generated.

Decitabine, a DNA methylation inhibitor, is being revisited as a targeted epigenetic therapy for cancer. Recent studies show its clinical activity in myelodysplastic syndrome and chronic myelogenous leukemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.

Cancer·2026
Same author

CDK9 degradation Inhibits Gastroesophageal Cancer growth and Overcomes Radiation Resistance by Increasing Chromatin Accessibility and Downregulating YAP1/TEAD signaling.

bioRxiv : the preprint server for biology·2025
Same author

ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer.

bioRxiv : the preprint server for biology·2024
Same author

Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1-mediated immune suppression during GVHD.

Blood·2023
Same author

TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype.

Gastroenterology·2023
Same author

Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Decitabine, a DNA methylation inhibitor, is an established cytosine analogue.
  • Epigenetic dysregulation, specifically DNA methylation, plays a crucial role in cancer development.
  • Advances in understanding DNA methylation have led to renewed interest in decitabine.

Purpose of the Study:

  • To review recent clinical and translational studies involving decitabine.
  • To highlight decitabine's mechanism of action as a targeted epigenetic therapy.
  • To discuss the evolving role of decitabine in cancer treatment.

Main Methods:

  • Review of recent clinical and translational studies.
  • Analysis of decitabine's mechanism of action (DNA methylation inhibition).

Related Experiment Videos

  • Examination of administration schedules and in vivo efficacy.

    • Main Results:

    • Decitabine demonstrates substantial clinical activity in myelodysplastic syndrome and chronic myelogenous leukemia (Phase II trials).
    • Investigating combinations of decitabine with histone deacetylase inhibitors and its use in sensitizing cells to other therapies.
    • Ongoing research to elucidate in vivo mechanisms of response to decitabine.

    Conclusions:

    • Decitabine has re-emerged as a targeted epigenetic therapy agent for cancer.
    • Optimal dosing, administration schedules, and rational combinations are crucial for decitabine therapy.
    • Decitabine serves as a prototype for epigenetic cancer therapies.